Category: by paywall status

More on SPIROCOR noninvasive heart disease test: Second retraction (in fact the first) says little

Since we first wrote about the travails of Spirocor’s bedside, noninvasive test for coronary artery disease, we’ve been trying, without much success, to find out more information.

But as they say about every dog, our day has come.

As we initially reported, Ron Waksman, a prominent Washington, D.C. cardiologist and editor-in-chief of Cardiovascular and Revascularization Medicine, was first author of one of two papers about the Spirocor technology that were published in 2010. The other, by Shiyovich, et al, was retracted earlier this month by the American Journal of the Medical Sciences, which triggered our interest in this case.

At the time, we couldn’t find any evidence that Waksman’s article had been retracted, and Waksman has not responded to multiple requests for comment. Today we spoke with Kate Coons, the journal’s managing editor, who told us that the authors had sought a retraction for the article, “An innovative noninvasive respiratory stress test indicates significant coronary artery disease,” in December, and that it had posted one on its website on Jan. 6 of this year. It will be in print in an upcoming issue.

The notice is not available on Medline, but it can be found on ScienceDirect: Continue reading More on SPIROCOR noninvasive heart disease test: Second retraction (in fact the first) says little

University of East London “looking into” Jatinder Ahluwalia’s career

We’re continuing to follow the case of Jatinder Ahluwalia. As we reported on Tuesday, Ahluwalia was dismissed from graduate school at the University of Cambridge years before a University College London (UCL) investigation found had renumbered files to deceive a co-author, and had likely sabotaged his colleagues’ work while manipulating his solutions to improve how his results looked. The results of that investigation came to light as part of a Nature retraction.

Ahluwalia now works — and studies plagiarism, in fact — at the school of health and bioscience at the University of East London. We asked Neville Punchard, the school’s dean, whether the university was aware of Ahluwalia’s past. Punchard replied by email: Continue reading University of East London “looking into” Jatinder Ahluwalia’s career

Scandinavian Journal of Immunology publishes Bulfone-Paus retraction notice

Silvia Bulfone-Paus

Last week, we reported that the Scandinavian Journal of Immunology had noted that a 2002 paper by Silvia Bulfone-Paus and colleagues had been retracted, but hadn’t yet published the retraction notice. A commenter tipped us off this week that the notice is out: Continue reading Scandinavian Journal of Immunology publishes Bulfone-Paus retraction notice

Exclusive: Researcher found guilty of misconduct at UCL had been dismissed from Cambridge for data fabrication

Here at Retraction Watch, we’ve been following the case of Jatinder Ahluwalia with interest. You may recall that an investigation by University College London (UCL) found “beyond reasonable doubt” that Ahluwalia had renumbered files to deceive a co-author. UCL was also “highly confident” that Ahluwalia had messed with his solutions to make his results look better, and sabotaged his colleagues’ work. The report of that investigation was part of a Nature retraction notice.

We’ve now learned that UCL was not the first scene of misconduct by Ahluwalia. Yesterday, we obtained letters by University of Cambridge faculty and administrators describing repeated — and in the words of of one professor, amateurish — data fabrication by Ahluwalia that led to his dismissal from the university’s graduate program.

In a letter dated November 10, 1997, Martin Brand, then Ahluwalia’s PhD advisor, wrote: Continue reading Exclusive: Researcher found guilty of misconduct at UCL had been dismissed from Cambridge for data fabrication

Unglaublich! Boldt investigation may lead to more than 90 retractions

Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg

Self-plagiarism alert: A very similar version of this post is being published online in Anesthesiology News, where one of us (AM) is managing editor.

Unglaublich is the German word for unbelievable, and it’s an apt description for the latest development in the case of Joachim Boldt.

Boldt, a prominent German anesthesiologist, has been at the center of a research and publishing investigation since last October, when the journal Anesthesia & Analgesia retracted a 2009 article of his over concerns of data manipulation. This morning, the German medical board overseeing the case, the Landesärztekammer Rheinland-Pfalz (LÄK-RLP),  released its findings — and they are truly stunning.

According to LAK, somewhere in the neighborhood of 90 of Boldt’s published articles might require retraction because the investigator failed to obtain approval from an institutional review board to conduct the research.

We don’t read German. But, fortunately, the LÄK-RLP announcement was accompanied by a joint letter posted to the websites of 11 major anesthesia journals. We do read English, and here’s what that letter says: Continue reading Unglaublich! Boldt investigation may lead to more than 90 retractions

Three more Bulfone-Paus retraction notices out, in Journal of Immunology

Silvia Bulfone-Paus

The retraction notices for papers by Silvia Bulfone-Paus continue to appear. Yesterday, the Journal of Immunology posted notices for these three previously accepted retractions by the researcher, work at whose Borstel Centre lab is under investigation for misconduct.

We wrote what? Breast cancer paper falls to rogue author

Something was fishy at China Normal University. According to the journal Anti-Cancer Drugs, a 2010 paper by researchers at the Beijing school — “3,30′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA21 in human breast cancer cells” — turned out to have suffered from an unfortunate anomaly. According to the retraction notice: Continue reading We wrote what? Breast cancer paper falls to rogue author

Georgia (well, the Medical College there, anyway) on our minds for a mysterious retraction

We’re watching a case which appears to involve more than meets the eye.

Molecular Endocrinology has retracted a 2010 study by researchers at the Medical College of Georgia. According to the Spartan retraction notice (we added a link): Continue reading Georgia (well, the Medical College there, anyway) on our minds for a mysterious retraction

And that’s 14: More (and more) Mori retractions, as Japanese cancer journal pulls three papers

Naoki Mori

The steady drip-drip-dripping sound you hear from the cancer literature these days comes from the stream of retractions involving studies by Naoki Mori, the now jobless scientist whose work on cancer viruses appears to be evaporating before our eyes.

Cancer Science, which used to be called the Japanese Journal of Cancer Research,  has retracted three more of Mori’s papers, each of which, according to the journal, contained multiple unreliable images. That brings the tally of retractions involving Mori’s articles to 14 by our count, an impressive number by any measure. Mori has more than 50 papers to his name, however, so it’s possible that the number of retractions will grow.

Here are the latest retractions: Continue reading And that’s 14: More (and more) Mori retractions, as Japanese cancer journal pulls three papers

Inability to reproduce Dutch grad student’s data prompts two retractions from the cancer lit

We are watching an intriguing case out of the Netherlands, involving a young researcher whose dubious results have led to the retraction of a pair of papers.

The retracted articles, which appeared in 2008 in Cancer Research and the British Journal of Cancer, come from the lab of the prominent Dutch scientist Ed Roos, of the Netherlands Cancer Institute in Amsterdam. Both papers addressed the actions of certain chemokine receptors — molecules on cell surfaces that interact with blood proteins involved in the immune response — on the behavior of tumor cells.

The first author on each paper was Joost Meijer, at the time a graduate student in Roos’ shop.

The retraction notices contain essentially the same information, although in the case of the BJC article — “Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo” — the letter is quite personal. Dated Jan. 4, 2011, it reads: Continue reading Inability to reproduce Dutch grad student’s data prompts two retractions from the cancer lit